Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ascendis Pharma A/S (ASND : NSDQ)
 
 • Company Description   
Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Number of Employees: 639

 
 • Price / Volume Information   
Yesterday's Closing Price: $91.13 Daily Weekly Monthly
20 Day Moving Average: 759,780 shares
Shares Outstanding: 56.94 (millions)
Market Capitalization: $5,188.73 (millions)
Beta: 0.86
52 Week High: $178.71
52 Week Low: $61.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.07% -3.21%
12 Week -14.98% -6.53%
Year To Date -32.26% -17.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
TUBORG BOULEVARD 12
-
HELLERUP,G7 2900
DNK
ph: 45-7022-2244
fax: 45-3694-4010
ir@ascendispharma.com http://www.ascendispharma.com
 
 • General Corporate Information   
Officers
Jan Moller Mikkelsen - President; Chief Executive Officer and Board Membe
Albert Cha - Chairman
Lisa Bright - Board Member
James I. Healy - Board Member
Lars Holtug - Board Member

Peer Information
Ascendis Pharma A/S (CORR.)
Ascendis Pharma A/S (RSPI)
Ascendis Pharma A/S (CGXP)
Ascendis Pharma A/S (BGEN)
Ascendis Pharma A/S (GTBP)
Ascendis Pharma A/S (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04351P101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/24/22
Share - Related Items
Shares Outstanding: 56.94
Most Recent Split Date: (:1)
Beta: 0.86
Market Capitalization: $5,188.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-2.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-8.92 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 14.99% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/24/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.87
Price/Cash Flow: -
Price / Sales: 328.36
EPS Growth
vs. Year Ago Period: -75.89%
vs. Previous Quarter: -15.89%
Sales Growth
vs. Year Ago Period: 752.17%
vs. Previous Quarter: 36.78%
ROE
03/31/22 - -54.58
12/31/21 - -45.19
09/30/21 - -50.72
ROA
03/31/22 - -39.31
12/31/21 - -37.05
09/30/21 - -42.10
Current Ratio
03/31/22 - 11.76
12/31/21 - 8.03
09/30/21 - 8.24
Quick Ratio
03/31/22 - 10.79
12/31/21 - 7.28
09/30/21 - 7.76
Operating Margin
03/31/22 - -3,281.45
12/31/21 - -5,015.63
09/30/21 - -12,211.21
Net Margin
03/31/22 - -3,281.45
12/31/21 - -5,015.63
09/30/21 - -12,211.21
Pre-Tax Margin
03/31/22 - -3,283.60
12/31/21 - -4,936.36
09/30/21 - -12,130.59
Book Value
03/31/22 - 13.26
12/31/21 - 18.38
09/30/21 - 20.64
Inventory Turnover
03/31/22 - 0.14
12/31/21 - 0.11
09/30/21 - 0.00
Debt-to-Equity
03/31/22 - 0.69
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 40.85
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©